Therapeutic options for the treatment of colorectal cancer(CRC) are diverse but still not always satisfying. Recent success of immune checkpoint inhibition treatment for the subgroup of CRC patients suffering from hyp...Therapeutic options for the treatment of colorectal cancer(CRC) are diverse but still not always satisfying. Recent success of immune checkpoint inhibition treatment for the subgroup of CRC patients suffering from hypermutated tumors suggests a permanent role of immune therapy in the clinical management of CRC. Substantial improvement in treatment outcome could be achieved by development of efficient patient-individual CRC vaccination strategies. This mini-review summarizes the current knowledge on the two general classes of targets: tumor-associated antigens(TAAs) and tumorspecific antigens. TAAs like carcinoembryonic antigen and melanoma associated antigen are present in and shared by a subgroup of patients and a variety of clinical studies examined the efficacy of different TAA-derived peptide vaccines. Combinations of several TAAs as the next step and the development of personalized TAA-based peptide vaccines are discussed. Improvements of peptidebased vaccines achievable by adjuvants and immunestimulatory chemotherapeutics are highlighted. Finally, we sum up clinical studies using tumor-specific antigens-in CRC almost exclusively neoantigens-which revealed promising results; particularly no severe adverse events were reported so far. Critical progress for clinical outcomes can be expected by individualizing neoantigen-based peptide vaccines and combining them with immunestimulatory chemotherapeutics and immune checkpoint inhibitors. In light of these data and latest developments, truly personalized neoantigen-based peptide vaccines can be expected to fulfill modern precision medicine's requirements and will manifest as treatment pillar for routine clinical management of CRC.展开更多
Patients exhibit good tolerance to messenger ribonucleic acid(m RNA)vaccines,and the choice of encoded molecules is flexible and diverse.These vaccines can be engineered to express full-length antigens containing mult...Patients exhibit good tolerance to messenger ribonucleic acid(m RNA)vaccines,and the choice of encoded molecules is flexible and diverse.These vaccines can be engineered to express full-length antigens containing multiple epitopes without major histocompatibility complex(MHC)restriction,are relatively easy to control and can be rapidly mass produced.In 2021,the U.S.Food and Drug Administration(FDA)approved the first m RNA-based coronavirus disease 2019(COVID-19)vaccine produced by Pfizer and Bio NTech,which has generated enthusiasm for m RNA vaccine research and development.Based on the above characteristics and the development of m RNA vaccines,m RNA cancer vaccines have become a research hotspot and have undergone rapid development,especially in the last five years.This review analyzes the advances in m RNA cancer vaccines from various perspectives,including the selection and expression of antigens/targets,the application of vectors and adjuvants,different administration routes,and preclinical evaluation,to reflect the trends and challenges associated with these vaccines.展开更多
T cell-redirecting bispecific antibodies are specifically designed to bind to tumor-associated antigens,thereby engaging with CD3 on the T cell receptor.This linkage between tumor cells and T cells actively triggers T...T cell-redirecting bispecific antibodies are specifically designed to bind to tumor-associated antigens,thereby engaging with CD3 on the T cell receptor.This linkage between tumor cells and T cells actively triggers T cell activation and initiates targeted killing of the identified tumor cells.These antibodies have emerged as one of the most promising avenues within tumor immunotherapy.However,despite success in treating hematological malignancies,significant advancements in solid tumors have yet to be explored.In this review,we aim to address the critical challenges associated with T cellredirecting bispecific antibodies and explore novel strategies to overcome these obstacles,with the ultimate goal of expanding the application of this therapy to include solid tumors.展开更多
Tumor-associated carbohydrate antigens(TACAs)provide a special class of tumor-specific antigens that show promising applications in cancer immunotherapy.However,the weak immunogenicity and structural complexity of TAC...Tumor-associated carbohydrate antigens(TACAs)provide a special class of tumor-specific antigens that show promising applications in cancer immunotherapy.However,the weak immunogenicity and structural complexity of TACAs are obstacles to their clinical application.Here,based on a fast and low-cost purification strategy for oligosaccharide synthesis,the synthesis of tumour-associated carbohydrate antigens Globo H and mannobiose which resembles repeat unit of mannan was achieved.To enhance the immunogenicity and multivalent effect,Globo H and mannobiose were covalently attached to degradable polymer backbones.2D spindle-like lamellar micelle and globular micelle were obtained from glycopolymer through a solvent-exchange method of self-assembly.The glyconanoparticle showed good biocompatibility and degradability.Immunological functions of these glyconanoparticles such as stimulation of BMDC to cause upregulation of inflammatory factors were preliminarily explored.展开更多
Photothermal therapy(PTT)-induced immune response has attracted much attention,however,which cannot work at full capacity.In this study,the simvastatin(SV)adjuvant is loaded into gold nanocages(AuNCs)to develop a simp...Photothermal therapy(PTT)-induced immune response has attracted much attention,however,which cannot work at full capacity.In this study,the simvastatin(SV)adjuvant is loaded into gold nanocages(AuNCs)to develop a simple drug delivery system,which can efficiently utilize the tumor-associated antigens(TAAs)for improving immune responses.AuNCs/SV-mediated PTT treatment enhances tumor cells damage and promotes the release of TAAs which are immediately captured by Au NCs/SV to form AuNCs/SV/TAAs recombinant nanoparticle.Impressively,AuNCs/SV/TAAs can accumulate in lymph nodes effectively due to the suitable size of~55 nm and hyperthermia-induced vasodilative effect.And the codelivery of antigen and adjuvant is beneficial to stimulating the maturation of dendritic cells for further activating T cells.In a word,the recombinant strategy could make full use of TAAs to produce an individual powerful immunotherapy.展开更多
基金Supported by Ministerium für Wirtschaft,Arbeit und Gesundheit Mecklenburg-Vorpommern,No.TBI-V-1-241-VBW-084
文摘Therapeutic options for the treatment of colorectal cancer(CRC) are diverse but still not always satisfying. Recent success of immune checkpoint inhibition treatment for the subgroup of CRC patients suffering from hypermutated tumors suggests a permanent role of immune therapy in the clinical management of CRC. Substantial improvement in treatment outcome could be achieved by development of efficient patient-individual CRC vaccination strategies. This mini-review summarizes the current knowledge on the two general classes of targets: tumor-associated antigens(TAAs) and tumorspecific antigens. TAAs like carcinoembryonic antigen and melanoma associated antigen are present in and shared by a subgroup of patients and a variety of clinical studies examined the efficacy of different TAA-derived peptide vaccines. Combinations of several TAAs as the next step and the development of personalized TAA-based peptide vaccines are discussed. Improvements of peptidebased vaccines achievable by adjuvants and immunestimulatory chemotherapeutics are highlighted. Finally, we sum up clinical studies using tumor-specific antigens-in CRC almost exclusively neoantigens-which revealed promising results; particularly no severe adverse events were reported so far. Critical progress for clinical outcomes can be expected by individualizing neoantigen-based peptide vaccines and combining them with immunestimulatory chemotherapeutics and immune checkpoint inhibitors. In light of these data and latest developments, truly personalized neoantigen-based peptide vaccines can be expected to fulfill modern precision medicine's requirements and will manifest as treatment pillar for routine clinical management of CRC.
文摘Patients exhibit good tolerance to messenger ribonucleic acid(m RNA)vaccines,and the choice of encoded molecules is flexible and diverse.These vaccines can be engineered to express full-length antigens containing multiple epitopes without major histocompatibility complex(MHC)restriction,are relatively easy to control and can be rapidly mass produced.In 2021,the U.S.Food and Drug Administration(FDA)approved the first m RNA-based coronavirus disease 2019(COVID-19)vaccine produced by Pfizer and Bio NTech,which has generated enthusiasm for m RNA vaccine research and development.Based on the above characteristics and the development of m RNA vaccines,m RNA cancer vaccines have become a research hotspot and have undergone rapid development,especially in the last five years.This review analyzes the advances in m RNA cancer vaccines from various perspectives,including the selection and expression of antigens/targets,the application of vectors and adjuvants,different administration routes,and preclinical evaluation,to reflect the trends and challenges associated with these vaccines.
基金supported by the National Natural Science Foundation of China(Nos.32070940 and 81991491)the China Postdoctoral Science Foundation(No.2021M700115)+2 种基金the Postdoctoral Innovation Talents Support Program(No.BX20220189,China)the Science and Technology Planning Project of Fujian Province(No.2022L3080,China)the CAMS Innovation Fund for Medical Sciences(No.2019RU022,China).
文摘T cell-redirecting bispecific antibodies are specifically designed to bind to tumor-associated antigens,thereby engaging with CD3 on the T cell receptor.This linkage between tumor cells and T cells actively triggers T cell activation and initiates targeted killing of the identified tumor cells.These antibodies have emerged as one of the most promising avenues within tumor immunotherapy.However,despite success in treating hematological malignancies,significant advancements in solid tumors have yet to be explored.In this review,we aim to address the critical challenges associated with T cellredirecting bispecific antibodies and explore novel strategies to overcome these obstacles,with the ultimate goal of expanding the application of this therapy to include solid tumors.
基金supported by the National Key Research and Development Program of China(No.2023YFA0915300)the National Natural Science Foundation of China(Nos.52125303 and 92356305)Innovation Program of Shanghai Municipal Education Commission(No.2023ZKZD02)。
文摘Tumor-associated carbohydrate antigens(TACAs)provide a special class of tumor-specific antigens that show promising applications in cancer immunotherapy.However,the weak immunogenicity and structural complexity of TACAs are obstacles to their clinical application.Here,based on a fast and low-cost purification strategy for oligosaccharide synthesis,the synthesis of tumour-associated carbohydrate antigens Globo H and mannobiose which resembles repeat unit of mannan was achieved.To enhance the immunogenicity and multivalent effect,Globo H and mannobiose were covalently attached to degradable polymer backbones.2D spindle-like lamellar micelle and globular micelle were obtained from glycopolymer through a solvent-exchange method of self-assembly.The glyconanoparticle showed good biocompatibility and degradability.Immunological functions of these glyconanoparticles such as stimulation of BMDC to cause upregulation of inflammatory factors were preliminarily explored.
基金financially supported by the National Natural Science Foundation of China(Nos.U1804183,81901878 and 81874304)China Postdoctoral Science Foundation(No.2019M662553)Key Scientific Research Project(Education Department of Henan Province,No.20HASTIT049)。
文摘Photothermal therapy(PTT)-induced immune response has attracted much attention,however,which cannot work at full capacity.In this study,the simvastatin(SV)adjuvant is loaded into gold nanocages(AuNCs)to develop a simple drug delivery system,which can efficiently utilize the tumor-associated antigens(TAAs)for improving immune responses.AuNCs/SV-mediated PTT treatment enhances tumor cells damage and promotes the release of TAAs which are immediately captured by Au NCs/SV to form AuNCs/SV/TAAs recombinant nanoparticle.Impressively,AuNCs/SV/TAAs can accumulate in lymph nodes effectively due to the suitable size of~55 nm and hyperthermia-induced vasodilative effect.And the codelivery of antigen and adjuvant is beneficial to stimulating the maturation of dendritic cells for further activating T cells.In a word,the recombinant strategy could make full use of TAAs to produce an individual powerful immunotherapy.
